Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

OBJECTIVE: To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), which includes patients with either anti-double-stranded DNA (anti-dsDNA) positivity or hypocomplem...

Descripción completa

Detalles Bibliográficos
Autores principales: Maslen, Toni, Bruce, Ian N, D'Cruz, David, Ianosev, Mihaela, Bass, Damon L, Wilkinson, Christel, Roth, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunology and Inflammation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878136/
https://www.ncbi.nlm.nih.gov/pubmed/33568389
http://dx.doi.org/10.1136/lupus-2020-000459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878136/
https://www.ncbi.nlm.nih.gov/pubmed/33568389
http://dx.doi.org/10.1136/lupus-2020-000459

Ejemplares similares